FDA approves Audenz for influenza A (H5N1).- Seqirus
Seqirus announced that the FDA has approved Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
Comment: This is the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain. Seqirus has combined two leading-edge technologies�MF59 adjuvant and cell-based antigen manufacturing�to create this pandemic influenza vaccine. Audenz is designed to be rapidly deployed to help protect the U.S. population, and can be stockpiled for first responders in the event of pandemic.